kabutan

Carna Biosciences, Inc.(4572) Summary

4572
TSE Growth
Carna Biosciences, Inc.
388
JPY
0
(0.00%)
May 1, 3:30 pm JST
2.46
USD
May 1, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
24.1
Yield
ー%
Margin Trading Ratio
Stock Price
May 1, 2026
Opening May 1, 9:00 am
386 JPY 2.45 USD
Previous Close Apr 30
388 JPY 2.41 USD
High May 1, 9:16 am
391 JPY 2.48 USD
Low May 1, 9:00 am
386 JPY 2.45 USD
Volume
24,400
Trading Value
9.00M JPY 0.06M USD
VWAP
387.9 JPY 2.47 USD
Minimum Trading Value
38,800 JPY 246 USD
Market Cap
7.45B JPY 0.05B USD
Number of Trades
102
Liquidity & Number of Trades
As of May 1, 2026
Liquidity
Slightly High
1-Year Average
469
1-Year High Dec 12, 2025
10,992
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 1,847,800
Apr 17, 2026 0 1,840,100
Apr 10, 2026 0 1,821,100
Apr 3, 2026 0 1,823,700
Mar 27, 2026 0 1,820,600
Company Profile
Carna Biosciences, Inc. specializes in drug discovery support services, primarily focusing on the production and sale of kinase proteins and analysis outsourcing. The company is also expanding into drug discovery.
Sector
Pharmaceuticals
Carna Biosciences, Inc. offers a diverse range of products and services supporting early-stage drug discovery, including the manufacture and sale of kinase proteins, assay development, profiling and screening services, and cell-based assay services. The company's strength lies in its extensive lineup of kinase proteins and assay kits. Additionally, Carna Biosciences is focusing on in-house drug discovery with kinase inhibitors, advancing research and development of new drugs in key disease areas such as cancer and immune-inflammatory disorders. For cancer-related projects, the company plans to conduct studies up to Phase II trials at most, while for other diseases, it aims to carry out Phase I trials or preclinical studies before out-licensing to pharmaceutical companies.